BACKGROUND: The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined. METHODS: From six Italian clinical centres, all consecutive patients starting salvage antiretroviral therapy after virological failure in the presence of the K65R mutation identified by a genotypic resistance test were selected. RESULTS: Among 145 subjects included over a 197 person-year follow-up, the estimated probability of virological response (VR, defined as reaching HIV RNA < 50 copies/ml after salvage therapy) at 24 and 48 weeks was 36% and 60%, respectively. The strongest independent predictor of VR was the inclusion of a thymidine analogue (TA) in the salvage regimen. The presence of M184V and the introduction of lopinavir/ritonavir as new drug were both marginally associated with better outcome. After 24 weeks of salvage therapy, the median reduction in HIV-1 RNA was -1.36 log10 copies/ml (interquartile range [IQR] 0.10-2.46): at multivariable regression analysis, salvage regimens containing a TA (beta = +0.80; P = 0.02) and lamivudine (beta = +1.21; P = 0.02) as new drug had a positive effect on the reduction of HIV-1 RNA. CONCLUSIONS: Development of the K65R mutation does not preclude a high rate of virological response to rescue therapy. Inclusion of a TA in the salvage regimen and the presence of a M184V mutation could have a favourable effect on virological outcome.
BACKGROUND: The effect of the HIV reverse transcriptase K65R mutation on virological response to salvage therapy has not been clearly defined. METHODS: From six Italian clinical centres, all consecutive patients starting salvage antiretroviral therapy after virological failure in the presence of the K65R mutation identified by a genotypic resistance test were selected. RESULTS: Among 145 subjects included over a 197 person-year follow-up, the estimated probability of virological response (VR, defined as reaching HIV RNA < 50 copies/ml after salvage therapy) at 24 and 48 weeks was 36% and 60%, respectively. The strongest independent predictor of VR was the inclusion of a thymidine analogue (TA) in the salvage regimen. The presence of M184V and the introduction of lopinavir/ritonavir as new drug were both marginally associated with better outcome. After 24 weeks of salvage therapy, the median reduction in HIV-1 RNA was -1.36 log10 copies/ml (interquartile range [IQR] 0.10-2.46): at multivariable regression analysis, salvage regimens containing a TA (beta = +0.80; P = 0.02) and lamivudine (beta = +1.21; P = 0.02) as new drug had a positive effect on the reduction of HIV-1 RNA. CONCLUSIONS: Development of the K65R mutation does not preclude a high rate of virological response to rescue therapy. Inclusion of a TA in the salvage regimen and the presence of a M184V mutation could have a favourable effect on virological outcome.
Authors: Philip M Grant; Jonathan Taylor; Andrew B Nevins; Vincent Calvez; Anne-Geneviève Marcelin; Marc Wirden; Andrew R Zolopa Journal: Antimicrob Agents Chemother Date: 2010-02-01 Impact factor: 5.191
Authors: Thangavel Samikkannu; Venkata S R Atluri; Adriana Y Arias; Kesava V K Rao; Carmen T Mulet; Rahul D Jayant; Madhavan P N Nair Journal: Curr HIV Res Date: 2014 Impact factor: 1.581
Authors: Venkata Subba Rao Atluri; Sudheesh P Kanthikeel; Pichili V B Reddy; Adriana Yndart; Madhavan P N Nair Journal: PLoS One Date: 2013-04-19 Impact factor: 3.240
Authors: Kathryn A Lindl; David R Marks; Dennis L Kolson; Kelly L Jordan-Sciutto Journal: J Neuroimmune Pharmacol Date: 2010-04-16 Impact factor: 4.147
Authors: Dimitrios Coutsinos; Cédric F Invernizzi; Daniela Moisi; Maureen Oliveira; Jorge L Martinez-Cajas; Bluma G Brenner; Mark A Wainberg Journal: PLoS One Date: 2011-05-31 Impact factor: 3.240